Essential fatty acids and abnormal involuntary movements in the general male population: A study of men born in 1933

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 55, Issue 1-2, 1996, Pages 83-87

  Nilsson, Agneta ^a,b   Horrobin, David F ^c   Rosengren, Annika ^b   Waller, Lotte ^b   Adlerberth, Annika ^b   Wilhelmsen, Lars ^b  

^a Karsudden Hospital   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Scotia Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; ESSENTIAL FATTY ACID; NEUROLEPTIC AGENT;

ADULT; ALCOHOL CONSUMPTION; CIGARETTE SMOKING; CONFERENCE PAPER; DIABETES MELLITUS; DYSKINESIA; FATTY ACID METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; SWEDEN;

EID: 0029741562     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90150-7     Document Type: Conference Paper

References (27)

1. Casey D. E. Tardive dyskinesia. In: Meltzer H. Y., ed. Psychopharmacology: The Third Generation of Progress, New York: Raven Press, 1987; 1411-1419.
2. Smith J. M., Baldessarini R. J. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980; 37: 1368-1373.
3. Kane J. M., Smith J. M. Tardive dyskinesia: Prevalence and risk factors, 1959-1979. Arch Gen Psychiatry 1982; 39: 473-481.
4. Richardson M. A., Pass R., Craig T. J., Vickers E. Psychopharmacol Bull 1984; 20: 33-38.
5. Yassa R., Nair V., Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics 1984; 25: 135-138.
6. Glazer W. M., Morgenstern H., Niedzwiecki D., Hughes J. Heterogeneity of tardive dyskinesia. A multivariate analysis. Br J Psychiatry 1988; 152: 253-259.
7. Dixon L., Weiden P. J., Haas G., Sweeney J., Frances A. J. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992; 33: 121-122.
8. Mukherjee S., Wisniewski A., Bilder R., Sackheim H. Possible association between tardive dyskinesia and altered carbohydrate metabolism. Arch Gen Psychiatry 1985; 42: 205.
9. Ganzini L., Heintz R. T., Hoffman W. F., Casey D. E. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry 1991; 48: 259-263.
10. Davis E. J. B., Borde M., Sharma L. N. Tardive dyskinesia and type II schizophrenia. Br J Psychiatry 1992; 160: 253-256.
11. Brown K. W., White T. The association between negative symptoms, movement disorders and frontal lobe psychological deficits in schizophrenic patients. Biol Psychiatry 1991; 30: 1182-1190.
12. Lohr J. B., Cadet J. L., Lohr M. A. et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophrenia Bull 1988; 14: 291-296.
13. Vaddadi K. S., Courtney P., Gilleard C. J., Manku M. M., Horrobin D. F. A double-blind trail of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 1989; 27: 313-323.
14. Vaddadi K. S. Essential fatty acids and alpha-tocopherol supplementation in tardive dyskinesia. In: Packer L., Prilipko L., Christen Y. eds. Free Radicals in the Brain Aging, Neurological and Mental Disorders. Berlin: Springer-Verlag, 1992: 74-90.
15. Kane J. M., Weinhold P., Kinon B., Wegner J., Leader M. Prevalence of abnormal involuntary movements ("spontaneous dyskinesi") in the normal elderly. Psychopharmacology 1982; 77: 105-108.
16. Yassa R. Tardive dyskinesia and anticholinergic drugs. L'Encephale 1988; 13: 233-239.
17. Owens-Cunningham D. G., Johnstone E. G., Frith D. C. Spontaneous involuntary disorders of movement. Their prevalence, severity and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 1982; 39: 452-461.
18. Waddington J. L. Schiophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflicts of paradigms. In: Smythies J. R., Bradely R. J. eds. International Review of Neurobiology. vol 31. San Diego: American Press, 1989: 297-353.
19. Nilsson A., Waller L., Rosengren A., Adlerberth A., Wilhelmsen L. Cigarette smoking is associated with abnormal involuntary movements in the general male population - a study of men born in 1933. 1995:submitted for publication.
20. Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare. Washington DC: US Government Printing Office. 1976; 534-537.
21. Manku M. S., Horrobin D. F., Huang Y. S., Morse N. Fatty acids in red cell membranes m normal humans. Lipids 1983; 18: 906-908.
22. Rosengren A., Wilhelmsen L., Eriksson E., Risberg B., Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ 1990; 301: 1248-1251.
23. Glen A. I. M., Glen E. M. T., MacDonell L. E. F., Skinner F. K. Essential fatty acid and alcoholism. In: Horrobin D. F. ed. Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine. New York: Wiley-Liss 1990: 321-332.
24. Halliwell B., Gutteridge J. M. C. Free Radicals in Biology and Medicine. Oxford University Press: Oxford, 1985.
25. Horrobin D. F., Glen A. I. M., Vaddadi K. S. The membrane hypothesis of schizophrenia. Schizophrenia Res 1994; 13: 195-207.
26. Church D. F., Pryor W. A. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985; 64: 111-126.
27. Pall H. S., Williams A. C., Blake D. R., Lunec J. Evidence of enhanced lipid peroxidataion in cerebrospinal fluid of patients taking phenothiazines. Lancet 1987; ii: 596-599.